Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2011-04-20 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2011-04-20 English
8-K Filing
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 18, 2011, reporting the appointment of a new Executive Vice President and Chief Operating Officer, Matthew W. Foehr. The content focuses on management changes, including compensation and stock option grants. There are no financial statements or detailed financial performance data. The primary subject is the change in senior management. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document is not a full financial report, earnings release, or regulatory filing of another type. Therefore, the correct classification is MANG with high confidence.
2011-04-18 English
8-K/A Filing
Regulatory Filings Classification · 95% confidence The document is an Amendment No. 2 to Form 8-K filed with the SEC, which is a Current Report under the Securities Exchange Act of 1934. It reports the completion of an acquisition (CyDex Pharmaceuticals) by Ligand Pharmaceuticals. The document includes references to audited financial statements of the acquired business and pro forma financial information as exhibits. The main content is about the acquisition event and related financial disclosures, typical of a Current Report (8-K) filing. It is not a full annual or quarterly report, nor a proxy, earnings release, or other specific report type. The 8-K form is generally classified under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories. The document length is 3634 characters, which is relatively short and consistent with an 8-K filing. Therefore, the best classification is Regulatory Filings (RNS).
2011-04-12 English
8-K/A Filing
Regulatory Filings Classification · 95% confidence The document is an Amendment No. 1 to Form 8-K, a Current Report filed with the SEC. It reports the completion of an acquisition (a merger) of CyDex Pharmaceuticals by Ligand Pharmaceuticals. It references audited financial statements and pro forma financial information as exhibits, but these are incorporated by reference and not included in full in the text. The document is 3634 characters long, which is relatively short and primarily serves as a regulatory announcement of the acquisition event and related filings. The presence of the Form 8-K and the description of the merger event point to a regulatory filing about a significant corporate event. Since it is a Form 8-K amendment reporting acquisition completion and related financial exhibits, it fits best under Regulatory Filings (RNS) as it does not contain the full financial statements or detailed financial analysis itself, but rather references them as exhibits. It is not a full Annual Report, Audit Report, or M&A filing like a merger proxy statement. Therefore, the best classification is Regulatory Filings (RNS).
2011-04-11 English
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes a licensing agreement, milestone payments, and financial obligations related to a merger and licensing fees. It includes specific financial figures and payment distributions but does not present comprehensive financial statements or a full financial report. The document is not an earnings release, annual report, or interim report but rather an update on a specific financial obligation triggered by a licensing event. This fits the category of Capital/Financing Update (CAP), as it relates to licensing fees and financial obligations arising from agreements and mergers. The document length is about 5,499 characters, which is consistent with a detailed 8-K filing rather than a brief announcement or a full report. Therefore, the best classification is CAP with high confidence.
2011-04-08 English
8-K Filing
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 31, 2011, reporting the entry into a material definitive agreement—a Loan and Security Agreement establishing a revolving line of credit facility. The content focuses on financing activity, specifically a loan agreement and borrowing details. There are no financial statements or earnings data presented, and the document is relatively short (3494 characters). This fits the category of a Capital/Financing Update rather than a full financial report or other categories. Therefore, the appropriate classification is CAP (Capital/Financing Update).
2011-04-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.